Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Elliott

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Gynecologic Oncology|April 6, 2024
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinomaRobert L Hollis, Richard Elliott, John C Dawson, et al.
Bioorganic & Medicinal Chemistry Letters|October 19, 2007
Potent achiral agonists of the ghrelin (growth hormone secretagogue) receptor. Part I: Lead identificationTom D Heightman, Jackie S Scott, Mark Longley, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFRMarian C Bryan, Daniel J Burdick, Bryan K Chan, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2010
Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2Jeffrey W Corbett, Kevin D Freeman-Cook, Richard Elliott, et al.
Nature Communications|July 8, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse modelsJoan Kyula-Currie, Victoria Roulstone, James Wright, et al.
Journal of Medicinal Chemistry|October 13, 2015
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case StudyRobert Heald, Krista K Bowman, Marian C Bryan, et al.
Nature Communications|May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Scientific Reports|July 15, 2018
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAnessHarriett Holme, Aditi Gulati, Rachel Brough, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2025
Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signalingVasudha Tandon, Alessandra Fistrovich, Joaquina Nogales, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|April 6, 2024
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinomaRobert L Hollis, Richard Elliott, John C Dawson, et al.
Bioorganic & Medicinal Chemistry Letters|October 19, 2007
Potent achiral agonists of the ghrelin (growth hormone secretagogue) receptor. Part I: Lead identificationTom D Heightman, Jackie S Scott, Mark Longley, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFRMarian C Bryan, Daniel J Burdick, Bryan K Chan, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2010
Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2Jeffrey W Corbett, Kevin D Freeman-Cook, Richard Elliott, et al.
Nature Communications|July 8, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse modelsJoan Kyula-Currie, Victoria Roulstone, James Wright, et al.
Journal of Medicinal Chemistry|October 13, 2015
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case StudyRobert Heald, Krista K Bowman, Marian C Bryan, et al.
Nature Communications|May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Scientific Reports|July 15, 2018
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAnessHarriett Holme, Aditi Gulati, Rachel Brough, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2025
Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signalingVasudha Tandon, Alessandra Fistrovich, Joaquina Nogales, et al.
Pageof 11